Free Trial

STAAR Surgical (STAA) Competitors

STAAR Surgical logo
$17.18 +0.40 (+2.35%)
As of 01:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

STAA vs. ICUI, XRAY, QDEL, NEOG, CERS, OSUR, UTMD, ANIK, WST, and COO

Should you be buying STAAR Surgical stock or one of its competitors? The main competitors of STAAR Surgical include ICU Medical (ICUI), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), Neogen (NEOG), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), Anika Therapeutics (ANIK), West Pharmaceutical Services (WST), and Cooper Companies (COO). These companies are all part of the "health care supplies" industry.

STAAR Surgical vs. Its Competitors

STAAR Surgical (NASDAQ:STAA) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

STAAR Surgical has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

ICU Medical has a net margin of -3.87% compared to STAAR Surgical's net margin of -25.46%. ICU Medical's return on equity of 6.75% beat STAAR Surgical's return on equity.

Company Net Margins Return on Equity Return on Assets
STAAR Surgical-25.46% -10.59% -8.32%
ICU Medical -3.87%6.75%3.20%

STAAR Surgical has higher earnings, but lower revenue than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$313.90M2.70-$20.21M-$1.44-11.89
ICU Medical$2.38B1.39-$117.69M-$3.83-35.15

STAAR Surgical presently has a consensus price target of $24.63, indicating a potential upside of 43.82%. ICU Medical has a consensus price target of $192.67, indicating a potential upside of 43.10%. Given STAAR Surgical's higher probable upside, equities research analysts clearly believe STAAR Surgical is more favorable than ICU Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STAAR Surgical
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ICU Medical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 96.1% of ICU Medical shares are held by institutional investors. 1.0% of STAAR Surgical shares are held by company insiders. Comparatively, 1.5% of ICU Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, STAAR Surgical had 4 more articles in the media than ICU Medical. MarketBeat recorded 5 mentions for STAAR Surgical and 1 mentions for ICU Medical. ICU Medical's average media sentiment score of 1.71 beat STAAR Surgical's score of 0.99 indicating that ICU Medical is being referred to more favorably in the news media.

Company Overall Sentiment
STAAR Surgical Positive
ICU Medical Very Positive

Summary

ICU Medical beats STAAR Surgical on 10 of the 17 factors compared between the two stocks.

Get STAAR Surgical News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STAA vs. The Competition

MetricSTAAR SurgicalMED/DENTAL IndustryMedical SectorNASDAQ Exchange
Market Cap$843.05M$15.66B$5.52B$8.87B
Dividend YieldN/A1.45%5.36%4.13%
P/E Ratio-11.8218.7226.5019.82
Price / Sales2.702.31410.19110.66
Price / CashN/A16.8925.8827.49
Price / Book2.123.677.945.39
Net Income-$20.21M$430.42M$3.15B$248.34M
7 Day Performance-0.34%2.49%1.08%1.25%
1 Month Performance-4.13%1.09%5.34%5.41%
1 Year Performance-63.89%19.71%32.80%18.07%

STAAR Surgical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAA
STAAR Surgical
3.9897 of 5 stars
$17.12
+2.0%
$24.63
+43.8%
-64.8%$843.05M$313.90M-11.821,211
ICUI
ICU Medical
4.5656 of 5 stars
$128.07
+0.3%
$192.67
+50.4%
+11.3%$3.14B$2.38B-33.4415,000Positive News
XRAY
DENTSPLY SIRONA
4.5733 of 5 stars
$15.48
+0.8%
$20.36
+31.5%
-36.3%$3.06B$3.79B-3.4114,000
QDEL
QuidelOrtho
4.3363 of 5 stars
$27.65
-1.4%
$44.33
+60.3%
-13.2%$1.90B$2.78B-5.566,600
NEOG
Neogen
3.8228 of 5 stars
$4.77
-3.4%
$9.00
+88.7%
-69.4%$1.07B$924.22M-2.142,110Analyst Forecast
High Trading Volume
CERS
Cerus
2.7594 of 5 stars
$1.34
flat
$3.50
+161.2%
-19.9%$256.15M$180.27M-13.40290Positive News
OSUR
OraSure Technologies
2.5129 of 5 stars
$3.03
+1.0%
$3.00
-1.0%
-29.6%$224.40M$185.83M-7.21840Positive News
UTMD
Utah Medical Products
2.8058 of 5 stars
$54.89
+2.3%
N/A-14.8%$174.23M$40.90M14.52180
ANIK
Anika Therapeutics
4.1042 of 5 stars
$10.92
+3.1%
$20.00
+83.2%
-58.2%$151.88M$119.91M-2.81300
WST
West Pharmaceutical Services
4.7275 of 5 stars
$217.05
+0.6%
$332.50
+53.2%
-33.6%$15.51B$2.89B34.0710,600
COO
Cooper Companies
3.5068 of 5 stars
$69.52
+0.1%
$99.70
+43.4%
-18.5%$13.89B$3.90B33.7516,000High Trading Volume

Related Companies and Tools


This page (NASDAQ:STAA) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners